STTK Shattuck Labs, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1680367 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-66.6%
TTM net income YoY14.5%
TTM EPS YoY63.6%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,578.7%
Net margin-5,256.8%
FCF margin—
EBITDA margin-5,221.0%
Returns
ROE-39.2%
ROA-36.9%
ROIC (approx.)-57.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets4.3%
Debt / equity0.00x
Current ratio27.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.00M | $5.72M | $1.66M | $652,000 | $30.02M |
| R&D expense | $35.27M | $67.21M | $74.31M | $82.90M | $56.56M |
| SG&A expense | $17.23M | $19.08M | $19.30M | $21.08M | $18.72M |
| Operating income | -$51.51M | -$80.57M | -$91.96M | -$103.33M | -$45.27M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$48.81M | -$75.41M | -$87.30M | -$101.94M | -$44.97M |
| EBITDA | -$47.81M | -$76.77M | -$87.96M | -$100.23M | -$43.87M |
| EPS (basic) | -0.70 | -1.49 | -2.05 | -2.41 | -1.07 |
| EPS (diluted) | -0.70 | -1.49 | -2.05 | -2.41 | -1.07 |
| Weighted avg. shares (diluted) | 69.58M | 50.76M | 42.60M | 42.38M | 42.03M |
| Balance sheet | |||||
| Cash & equivalents | $54.19M | $57.39M | $125.63M | $47.38M | $92.27M |
| Short-term investments | — | — | $5.00M | $113.90M | $176.54M |
| Current assets | $82.47M | $79.22M | $143.22M | $184.58M | $288.27M |
| PP&E, net | $6.11M | $9.81M | $13.80M | $17.67M | $9.94M |
| Total assets | $91.03M | $91.05M | $159.56M | $205.32M | $298.58M |
| Current liabilities | $7.05M | $8.92M | $11.45M | $24.96M | $24.59M |
| Total liabilities | $8.64M | $11.42M | $14.86M | $29.17M | $26.80M |
| Shareholders' equity | $82.39M | $79.63M | $144.71M | $176.16M | $271.79M |
| Shares outstanding | 63.28M | 47.71M | 47.26M | 42.39M | 42.34M |
| Cash flow statement | |||||
| Operating cash flow | -$39.88M | -$60.52M | -$81.23M | -$94.50M | -$57.12M |
| Capital expenditure | $71,000 | $59,000 | $407,000 | $11.61M | $7.93M |
| Free cash flow | -$39.95M | -$60.57M | -$81.64M | -$106.11M | -$65.04M |
| Investing cash flow | -$7.89M | -$8.51M | $110.86M | $49.44M | -$10.44M |
| Financing cash flow | $44.57M | $787,000 | $48.62M | $171,000 | $1.93M |
| Depreciation & amortization | $3.70M | $3.80M | $4.00M | $3.10M | $1.40M |
| Stock-based compensation | $7.00M | $9.55M | $6.94M | $6.46M | $5.47M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.